Puma Biotechnology (PBYI) Non-Current Debt (2011 - 2025)

Puma Biotechnology's Non-Current Debt history runs 10 years deep, the most recent figure standing at $10.9 million for Q2 2025.

• Quarterly Non-Current Debt fell 75.15% year-over-year to $10.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $10.9 million (down 75.15% YoY) and the FY2024 annual result came in at $21.7 million, down 66.92% from the prior year.
• Non-Current Debt was $10.9 million for Q2 2025 at Puma Biotechnology, up from $10.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $98.6 million in Q1 2023 and bottomed at $10.6 million in Q1 2025.
• A 5-year average of $68.5 million and a median of $76.5 million in 2021 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt jumped 42.17% — and 2025, when it slumped 80.53%.
• Puma Biotechnology's Non-Current Debt stood at $97.1 million in 2021, then advanced by 1.25% to $98.3 million in 2022, then sank by 33.21% to $65.7 million in 2023, then plunged by 66.92% to $21.7 million in 2024, then slumped by 49.96% to $10.9 million in 2025.
• Business Quant data shows PBYI's Non-Current Debt at $10.9 million in Q2 2025, $10.6 million in Q1 2025, and $21.7 million in Q4 2024.